

**Key highlights of data accepted by ASCO include**

<b>Medicine</b>	<b>Abstract Title</b>	<b>Abstract Number/ Presentation Details</b>
Kisqali® (ribociclib)*	Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age	Abstract #516 Rapid Oral June 1, 8:00 – 9:30am CDT
Kisqali® (ribociclib)	Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2- early breast cancer (EBC) eligible for NATALEE	Abstract #527 Poster Presentation June 2, 9:00am – 12:00pm CDT
Kisqali® (ribociclib)	Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2- early breast cancer (EBC)	Abstract #TPS617 Poster Presentation June 2, 9:00am – 12:00pm CDT
Kisqali® (ribociclib)	First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2- advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice	Abstract #1069 Poster Presentation June 2, 9:00am – 12:00pm CDT
Scemblix® (asciminib)	Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial	Abstract #6516 Rapid Oral May 30, 1:00 – 2:30pm CDT
Scemblix® (asciminib)	Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)	Abstract #6501 Oral Presentation June 2, 3:00 – 6:00pm CDT
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy exposure: a real-world	Abstract #e17030 Online Publication

	PRostatE Cancer dISease observatIOn (PRECISION) data platform analysis	
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617: a real-world PRostatE Cancer dISease observatIOn (PRECISION) data platform analysis	Abstract #e17035 Online Publication
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC)	Abstract #TPS5127 Poster Presentation June 2, 9:00am – 12:00pm CDT

**Key highlights of data accepted by EHA include**

<b>Medicine</b>	<b>Abstract Title</b>	<b>Abstract Number/ Presentation Details</b>
Fabhalta® (iptacopan)	APPULSE-PNH: Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin (Hb) increases in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and Hb ≥10 g/dL on anti-C5 therapy	Abstract #S183 Oral Presentation June 13, 5:00 – 6:15pm CEST
Fabhalta® (iptacopan)	The 2-year safety and efficacy of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) from APPLY- and APPOINT-PNH studies who entered the roll-over extension program (REP)	Abstract #PF660 Poster Presentation June 13, 6:30 – 7:30pm CEST
Scemblix® (asciminib)	Asciminib (ASC) shows superior tolerability vs nilotinib (NIL) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Primary endpoint results of the phase (Ph) 3b ASC4START trial	Abstract #S166 Oral Presentation June 13, 5:00 – 6:25pm CEST
Scemblix® (asciminib)	Improved patient-reported outcomes (PROs) with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed	Abstract #PS1588 Poster Presentation June 14, 6:30 – 7:30pm CEST

	chronic myeloid leukemia (CML): ASC4FIRST wk 48 analysis	
Scemblix® (asciminib)	Interim analysis (IA) results from ASC2ESCALATE support asciminib (ASC) as a treatment (Tx) option in chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI)	Abstract #PF595 Poster Presentation June 13, 6:30 – 7:30pm CEST
Pelabresib (DAK539)	Pelabresib in combination with ruxolitinib for janus kinase inhibitor- naive patients with myelofibrosis: 72- week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study	Abstract #S223 Oral Presentation June 12, 5:00 – 6:15pm CEST
Ianalumab (VAY736)	A Phase 2 Study of Ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy (VAYHIT3)	Abstract #S312 Oral Presentation June 15, 11:00am – 12:15pm CEST
Rapcabtagene autoleucel (YTB323)	Rapcabtagene Autoleucel (YTB323) in patients with relapsed/refractory diffuse large B-cell lymphoma: A phase II trial clinical update	Abstract #PF1152 Poster Presentation June 13, 6:30 – 7:30pm CEST